Haluk Tezcan, MD

Bio

Clinical focus:
Breast Oncology
Molecular Diagnostics

Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.

He is leading the development of Lexent Bio's liquid biopsy technology, first in response monitoring, overseeing scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director both in academia and private practice, he has firsthand understanding of unmet clinical needs of physicians and patients, and broad experience in clinical trial design and implementation.
He established the CA.RE.foundation, a cancer research foundation dedicated to enabling clinical trial execution across community oncology sites throughout the Northwest US. He’s independently built multiple software tools to help oncologists in the practical realities of their daily work.

Before Lexent Bio, he has served as Director of Translational Medicine at Genomic Health and as Vice President leading oncology development at Counsyl, integrating science with clinical product development. He is a steering committee member of the ASCO QOPI, a quality care initiative.

Clinical Focus

• Medical Oncology

Professional Education

• Board Certification: American Board of Internal Medicine, Medical Oncology (2023)
• Board Certification: American Board of Internal Medicine, Hematology (2016)
• Residency: University of British Columbia (1994) BC Canada
• Residency: University of Nebraska Medical Center Internal Medicine Residency (1992) NE
• Fellowship: SUNY Buffalo Roswell Park Cancer Institute (1995) NY
• Medical Education: Istanbul University, Istanbul Medical Faculty (1986) Turkey